

U.S.S.N. 10/632,878

Filed: August 1, 2003

**AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT****Remarks****Response to Restriction Requirement**


In the Office Action mailed May 3, 2005, the claims were divided into two groups, Group I, claims 1-36, drawn to a method for transporting compounds across a membrane/lipid bilayer, and Group II, claim 37, drawn to a composition for transporting a compound across a membrane/lipid bilayer.

In response, Applicants elect Group I, claims 1-36, without traverse. Claim 37 has been canceled. Applicants reserve the right to pursue the canceled subject matter in a divisional application.

Page 7, lines 1-4 was amended to correct an obvious typographical error in the chemical structure and molecular weight of 3,6-Bis{N-Fumaryl-N-(n-butyl)amino}-2,5-diketopiperazine. No new matter has been added.

Favorable consideration of claims 1-36 is respectfully solicited.

Respectfully submitted,

  
Rivka D. Monheit  
Reg. No. 48,731

Date: June 3, 2005

PABST PATENT GROUP, LLP  
400 Colony Square, Suite 1200  
1201 Peachtree Street  
Atlanta, Georgia 30361  
(404) 879-2152  
(404) 879-2160 (fax)